Microvascular Monitoring in Circulatory Shock and Sepsis (MiMICSS)

Sponsor
University of Manitoba (Other)
Overall Status
Recruiting
CT.gov ID
NCT05985525
Collaborator
(none)
100
1
36.1
2.8

Study Details

Study Description

Brief Summary

Investigation of the feasibility of using near-infrared spectroscopy (NIRS) to monitor microvascular function in critically ill patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Skeletal muscle and cerebral NIRS (research device)

Detailed Description

This is a prospective observational study using non-invasive NIRS for microvascular monitoring in the ICU. The study involves no interventions above standard of care other than the application of the NIRS monitors.

NIRS will be applied to skeletal muscle and the brain longitudinally throughout ICU admission. Vital signs are extracted continuously from the ICU monitor and clinical data are recorded from patient records.

The broad goals of the study are:
  1. Determine the feasibility of longitudinal NIRS monitoring in ICU patients

  2. Determine the ability to derive patient-specific microvascular metrics using NIRS

  3. Explore the relationship between microvascular metrics and ICU mortality

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Microvascular Monitoring in Circulatory Shock and Sepsis (MiMICSS): Prospective Observational Cohort Study
Actual Study Start Date :
May 27, 2022
Anticipated Primary Completion Date :
May 31, 2025
Anticipated Study Completion Date :
May 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Observational

All patients

Device: Skeletal muscle and cerebral NIRS (research device)
NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
Other Names:
  • PortaMon (Artinis Inc, Netherlands)
  • PortaLite (Artinis Inc, Netherlands)
  • Outcome Measures

    Primary Outcome Measures

    1. Recruitment [30 days]

      Recruitment of two patients per month from each study site

    Secondary Outcome Measures

    1. protocol adherence [14 days]

      collection of NIRS and clinical data for each monitoring session

    2. NIRS and vital sign data quality [14 days]

      NIRS and vital sign data is >50% free of artifacts for >80% of recording sessions to enable further analysis

    3. Optimal Map (MAPopt) derivation [14 days]

      when MAP and NIRS data available together, ability to derive MAPopt from >80% of recording sessions using correlation analysis

    Other Outcome Measures

    1. ICU mortality [30 days]

      ICU mortality status

    2. Hospital mortality [100 days]

      Hospital mortality

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Admitted to ICU

    • Receiving invasive mechanical ventilation

    Exclusion Criteria:
    • Body Mass Index >40

    • More than 24 hours has elapsed since ICU admission

    • Death is deemed to be imminent and inevitable during the next 24 hours

    • Known allergy to the textile components of the device

    • Significant clinical jaundice, ecchymosis

    • COVID positive microbiological result

    • The treating clinician believes that participation in the domain would not be in the best interests of the patient

    • Consent declined from patient or authorized third party

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Health Sciences Centre Winnipeg Winnipeg Manitoba Canada R3A 1R9

    Sponsors and Collaborators

    • University of Manitoba

    Investigators

    • Principal Investigator: Asher Mendelson, MD, PhD, University of Manitoba

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Asher Mendelson, Assistant Professor, University of Manitoba
    ClinicalTrials.gov Identifier:
    NCT05985525
    Other Study ID Numbers:
    • HS25043
    First Posted:
    Aug 14, 2023
    Last Update Posted:
    Aug 14, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Asher Mendelson, Assistant Professor, University of Manitoba
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 14, 2023